Back to results
US 11,598,767 B2Granted
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
AssigneeHorizon Therapeutics USA, Inc.
InventorsTheresa Rosario-Jansen, David Erick Wright
Life of this patent
Estimating the term…
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Claims4
A method of treating a patient suffering from chronic gout refractory to conventional therapy (GRT), comprising:
- administering to the patient 8 mg of pegloticase every 2 weeks by intravenous infusion;
- measuring the serum uric acid (SUA) level of the patient every 2 weeks after said administration, and
- discontinuing said administration if said SUA level of the patient is above 6 mg/dl.
A method of treating a patient suffering from chronic gout refractory to conventional therapy (GRT), comprising:
- administering to the patient 8 mg of pegloticase every 2 weeks by intravenous infusion;
- monitoring the serum uric acid (SUA) level of the patient after said administration;
- and
- discontinuing said administration when the serum uric acid (SUA) level of the patient is above 6 mg/dl.
1 more element
Dependencies are inferred from the claim text.